{"id":"prodiax-23","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL22016","moleculeType":"Small molecule","molecularWeight":"498.57"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the PI3K/AKT pathway, Prodiax-23 aims to reduce tumor growth and proliferation. This mechanism is being explored in the treatment of various cancers.","oneSentence":"Prodiax-23 is a small molecule that targets the PI3K/AKT pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:30:15.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 3 clinical trials for metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT04875858","phase":"PHASE4","title":"Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2021-05-01","conditions":"Pneumococcal Infections","enrollment":254},{"nctId":"NCT04551248","phase":"","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2021-08-01","conditions":"Pneumococcal Vaccine Adverse Reaction","enrollment":1000000},{"nctId":"NCT02079207","phase":"PHASE3","title":"Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2013-12","conditions":"Pneumococcal Infections","enrollment":767}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BIPOLAR DISORDER"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Prodiax-23","genericName":"Prodiax-23","companyName":"SK Chemicals Co., Ltd.","companyId":"sk-chemicals-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Prodiax-23 is a small molecule that targets the PI3K/AKT pathway. Used for Phase 3 clinical trials for metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}